Literature DB >> 24425422

Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly.

Chien-Hsieh Chiang1, Long-Teng Lee, Shou-Hung Hung, Wen-Yuan Lin, Hui-Fang Hung, Wei-Shiung Yang, Pei-Kun Sung, Kuo-Chin Huang.   

Abstract

UNLABELLED: Limited data exist regarding metabolic risk factors for deaths from hepatocellular carcinoma (HCC) in aging individuals. We investigated the association between diabetes, dyslipidemia, and HCC mortality in those aged 40 years or more (middle-aged and elderly). In this prospective cohort study based on nationwide health screening units, we consecutively followed middle-aged and elderly participants who had no chronic hepatitis B or C virus infection and received health screening from January 1 1998 to December 31 2008. There were 235 deaths from HCC among 50,080 individuals, ascertained by validated death certificates and the national death registry. Diabetes (adjusted hazard ratio [HR], 3.38; 95% confidence interval [CI], 2.35 to 4.86) was positively associated with deaths from HCC. However, hypertriglyceridemia (HR, 0.38; 95% CI, 0.26 to 0.55) and hypercholesterolemia (HR, 0.50; 95% CI, 0.37 to 0.67) were inversely associated with HCC mortality. The above significant associations remained in the lag time analyses, applied to check for reverse causation. Metabolic syndrome, as defined by the American Heart Association / National Heart Lung Blood Institute criteria (HR, 0.63; 95% CI, 0.46 to 0.86) or by the International Diabetes Federation criteria (HR, 0.62; 95% CI, 0.43 to 0.89), was inversely associated with deaths from HCC, especially in men.
CONCLUSION: Middle-aged and elderly individuals, once having diabetes, deserve HCC surveillance to reduce HCC mortality. More research is needed to elucidate why having baseline dyslipidemia relates to lower future HCC mortality.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24425422     DOI: 10.1002/hep.27014

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

Review 1.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

2.  Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults.

Authors:  Peter T Campbell; Christina C Newton; Neal D Freedman; Jill Koshiol; Michael C Alavanja; Laura E Beane Freeman; Julie E Buring; Andrew T Chan; Dawn Q Chong; Mridul Datta; Mia M Gaudet; J Michael Gaziano; Edward L Giovannucci; Barry I Graubard; Albert R Hollenbeck; Lindsey King; I-Min Lee; Martha S Linet; Julie R Palmer; Jessica L Petrick; Jenny N Poynter; Mark P Purdue; Kim Robien; Lynn Rosenberg; Vikrant V Sahasrabuddhe; Catherine Schairer; Howard D Sesso; Alice J Sigurdson; Victoria L Stevens; Jean Wactawski-Wende; Anne Zeleniuch-Jacquotte; Andrew G Renehan; Katherine A McGlynn
Journal:  Cancer Res       Date:  2016-10-15       Impact factor: 12.701

3.  Diabetes and hepatocellular carcinoma risks in patients with nonalcoholic steatohepatitis related cirrhosis.

Authors:  Chien-Hsieh Chiang; Kuo-Chin Huang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

4.  Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.

Authors:  I Doycheva; J Cui; P Nguyen; E A Costa; J Hooker; H Hofflich; R Bettencourt; S Brouha; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-09-15       Impact factor: 8.171

5.  Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies.

Authors:  Tracey G Simon; Lindsay Y King; Dawn Q Chong; Long H Nguyen; Yanan Ma; Trang VoPham; Edward L Giovannucci; Charles S Fuchs; Jeffrey A Meyerhardt; Kathleen E Corey; Hamed Khalili; Raymond T Chung; Xuehong Zhang; Andrew T Chan
Journal:  Hepatology       Date:  2018-03-26       Impact factor: 17.425

Review 6.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

7.  Diabetes and liver cancer risk: A stronger effect in Whites than Blacks?

Authors:  Rebecca Baqiyyah N Conway; Staci Sudenga; Donald McClain; William J Blot
Journal:  J Diabetes Complications       Date:  2020-12-01       Impact factor: 2.852

8.  Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk.

Authors:  Duaa S Nasereldin; Launia J White; David O Hodge; Lewis R Roberts; Tushar Patel; Samuel O Antwi
Journal:  Dig Liver Dis       Date:  2021-12-23       Impact factor: 5.165

9.  Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma after curative hepatectomy.

Authors:  Yan-Yan Wang; Shan Huang; Jian-Hong Zhong; Yang Ke; Zhe Guo; Jia-Qi Liu; Liang Ma; Hang Li; Bing-Ning Ou; Le-Qun Li
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

10.  Prediction of the risk of developing hepatocellular carcinoma in health screening examinees: a Korean cohort study.

Authors:  Chansik An; Jong Won Choi; Hyung Soon Lee; Hyunsun Lim; Seok Jong Ryu; Jung Hyun Chang; Hyun Cheol Oh
Journal:  BMC Cancer       Date:  2021-06-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.